Nationwide Fund Advisors lifted its position in Cambrex Corporation (NYSE:CBM) by 3.1% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 178,016 shares of the biotechnology company’s stock after acquiring an additional 5,275 shares during the quarter. Nationwide Fund Advisors owned 0.55% of Cambrex Corporation worth $10,636,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also recently modified their holdings of CBM. Great West Life Assurance Co. Can grew its position in shares of Cambrex Corporation by 7.4% in the 1st quarter. Great West Life Assurance Co. Can now owns 45,731 shares of the biotechnology company’s stock worth $2,515,000 after acquiring an additional 3,132 shares in the last quarter. State Board of Administration of Florida Retirement System grew its position in shares of Cambrex Corporation by 123.2% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 50,931 shares of the biotechnology company’s stock worth $2,804,000 after acquiring an additional 28,115 shares in the last quarter. First Trust Advisors LP acquired a new position in shares of Cambrex Corporation in the 1st quarter worth approximately $1,154,000. Suntrust Banks Inc. grew its position in shares of Cambrex Corporation by 11.6% in the 1st quarter. Suntrust Banks Inc. now owns 7,154 shares of the biotechnology company’s stock worth $393,000 after acquiring an additional 745 shares in the last quarter. Finally, BNP Paribas Arbitrage SA grew its position in shares of Cambrex Corporation by 6.8% in the 1st quarter. BNP Paribas Arbitrage SA now owns 6,436 shares of the biotechnology company’s stock worth $354,000 after acquiring an additional 408 shares in the last quarter. Institutional investors own 98.28% of the company’s stock.
Several brokerages have recently commented on CBM. ValuEngine lowered Cambrex Corporation from a “buy” rating to a “hold” rating in a research report on Friday, September 1st. BidaskClub downgraded Cambrex Corporation from a “hold” rating to a “sell” rating in a report on Thursday, August 24th. Finally, Zacks Investment Research downgraded Cambrex Corporation from a “buy” rating to a “hold” rating in a report on Tuesday, July 4th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $64.00.
Shares of Cambrex Corporation (NYSE:CBM) opened at 54.25 on Tuesday. The company has a 50 day moving average price of $53.13 and a 200 day moving average price of $55.08. The company has a market cap of $1.78 billion, a P/E ratio of 19.76 and a beta of 2.25. Cambrex Corporation has a one year low of $38.30 and a one year high of $62.95.
Cambrex Corporation (NYSE:CBM) last released its quarterly earnings data on Friday, August 4th. The biotechnology company reported $0.76 earnings per share for the quarter, meeting the consensus estimate of $0.76. Cambrex Corporation had a return on equity of 24.25% and a net margin of 17.70%. The company had revenue of $134.55 million for the quarter, compared to analyst estimates of $136.82 million. During the same period in the prior year, the company posted $0.68 EPS. The company’s revenue was up 13.4% compared to the same quarter last year. Equities research analysts expect that Cambrex Corporation will post $3.08 earnings per share for the current year.
In other news, CEO Steven M. Klosk sold 12,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 1st. The stock was sold at an average price of $61.39, for a total value of $736,680.00. Following the sale, the chief executive officer now directly owns 95,328 shares in the company, valued at approximately $5,852,185.92. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Over the last quarter, insiders sold 36,000 shares of company stock worth $2,070,960. Corporate insiders own 2.48% of the company’s stock.
Cambrex Corporation Profile
Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.
Want to see what other hedge funds are holding CBM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cambrex Corporation (NYSE:CBM).
Receive News & Ratings for Cambrex Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex Corporation and related companies with MarketBeat.com's FREE daily email newsletter.